susoctocog alfa susoctocog alfa susoctocog alfa, sold under the brand name obizur, is a medication used for the treatment of bleeding episodes in adults with acquired haemophilia, a bleeding disorder caused by the spontaneous development of antibodies that inactivate factor viii. susoctocog alfaclinical datatrade namesobizurother namesantihemophilic factor (recombinant)ahfs/drugs.commonographlicense data eu ema: by inn us dailymed: obizur pregnancycategory au: b2 drug classantihemophilic factoratc codeb02bd14 (who) legal statuslegal status au: s4 (prescription only) uk: pom (prescription only) us: ℞-only eu: rx-only in general: ℞ (prescription only) identifierscas number1339940-90-7drugbankdb11606unii6892uqt2gkkeggd10831 susoctocog alfa was approved for medical use in the united states in october 2014, and for medical use in the european union in november 2015. factor viii is one of the proteins needed for normal clotting of the blood.